Small-cap biotech firm Peregrine Pharmaceuticals (NASDAQ: PPHM) was the leading gainer on the Nasdaq on Monday after the company updated investors on data problems with its Phase II clinical trial of its lead cancer drug bavituximab. …
Investors in Peregrine Pharmaceuticals Inc. PPHM need to pay close attention to the stock based on moves in the options market lately. That is because the June 16th, 2017 $1 Call had some of the highest implied volatility of all …
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PPHM at https://www.zacks.com/ap/PPHM
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PPHM at https://www.zacks.com/ap/PPHM Keywords: Peregrine, Earnings …
Its stock fell 0.9 percent to $90.87 and was the top drag on the ... Among the largest decliners on Monday was Peregrine Pharmaceuticals Inc PPHM.O, which plunged 78.5 percent to $1.16 after the company said it found major …
The company’s common stock and preferred stock will continue to trade under the ticker symbols “PPHM” and “PPHMP”, respectively, until market close on Friday, January 5, 2018. The corporate name change to Avid Bioservices does not …
A year ago, they were trading at $1.22. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PPHM at https://www.zacks.com/ap/PPHM